Clinical Trials Browser

Ovarian Carcinosarcoma

NCT05819892 2026-05-29

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1 Recruiting

21 enrolled

Gynecologic

Endometrial Neoplasms

NCT05277051 2026-05-22

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

152 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Clinical Trials

ROCSAN

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

DOVE

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

STAR

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

FIRST

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

DOMENICA

RODEO

RUBY-J

OPAL

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)